An Overview of drug discovery efforts for eczema: why is this itch so difficult to scratch?
Publication in refereed journal


引用次數
Scopus ( 25/10/2020)
替代計量分析
.

其它資訊
摘要Introduction: Atopic dermatitis (AD) is a type of allergic/inflammatory dermatitis characterized by itch and an impairment in quality of life.

Areas covered: Herein, the authors review drug discovery efforts for AD, highlighting the clinical efficacy of novel drugs, with a particular focus on the relief of pruritus. Topical agents include emollients, topical antihistamines, corticosteroids, calcineurin inhibitors and herbs. Recently, topical phosphodiesterase E4 (PDE4) inhibitors like crisaborole have become available and are efficacious for mild to moderate AD with few side effects. For more severe AD, monoclonal antibodies like dupilumab are considered as efficacious subcutaneous treatment options. In severe and recalcitrant AD, systemic treatment can ameliorate AD symptoms.

Expert opinion: Many topical and systemic medications have demonstrated therapeutic benefits for AD. Indeed, randomized trials have shown that topical PDE4 inhibitors and subcutaneous dupilumab are safe and efficacious. Objective tools to evaluate itch and gauge treatment efficacy is important, but current methodology relies primarily on clinical scores. AD is a systemic atopic disease with a lot of complicated psychosocial issues. Suboptimal efficacy is often due to poor compliance and unrealistic expectation of curative treatment, rendering treatment difficult despite the existence of effective medications.
著者Hon KL, Loo S, Leung AKC, Li JTS, Lee VWY
期刊名稱Expert Opinion on Drug Discovery
出版年份2020
月份4
卷號15
期次4
出版社Taylor & Francis
頁次487 - 498
國際標準期刊號1746-0441
電子國際標準期刊號1746-045X
語言美式英語

上次更新時間 2020-26-10 於 00:11